
MTS @boltz_bio | Prev: @GeorgiaTech
London, United Kingdom
Joined February 2017
- Tweets97
- Following348
- Followers240
- Likes274
Pinned Tweet
Excited to share STAR-MD: a scalable autoregressive diffusion model that generates stable, high-quality protein MD trajectories at microsecond timescales, where existing methods fail catastrophically.
Accepted at ICLR 2026! Links and details in the thread 🧵👇
1/7
Nima Shoghi retweeted
We built Boltz to put our models in the hands of every scientist. This latest funding round is a major step toward that goal, giving us the resources to push our research further, build more powerful tools, and continue to grow our fantastic team.
We’ve raised $110M to bring AI-powered biomolecular design to every scientist!
Boltz’s Series A is led by @BessemerVP, following 50-fold growth in molecular token usage from our users since June and partnerships with 6 of the world’s 20 largest pharma companies.
Nima Shoghi retweeted
More money for better models for more "50-fold growth in token usage" for more money for better models for more ... 🙃
We’ve raised $110M to bring AI-powered biomolecular design to every scientist!
Boltz’s Series A is led by @BessemerVP, following 50-fold growth in molecular token usage from our users since June and partnerships with 6 of the world’s 20 largest pharma companies.
Nima Shoghi retweeted
Huge day for Boltz as we announce our Series A! 🚀
This month marks 6 months since I joined. Seeing what this team has built makes me even more excited for the next 6. More compute, more data, and the chance to push much further in biomolecular design. Let's go! 🇬🇧
We’ve raised $110M to bring AI-powered biomolecular design to every scientist!
Boltz’s Series A is led by @BessemerVP, following 50-fold growth in molecular token usage from our users since June and partnerships with 6 of the world’s 20 largest pharma companies.
Nima Shoghi retweeted
We’ve raised $110M in a Series A led by Bessemer Venture Partners to bring AI-powered biomolecular design to every scientist!
6 of the world’s top 20 pharma companies are partners. Molecular token usage has grown 50-fold since June.
boltz.com/series-a
We’ve raised $110M to bring AI-powered biomolecular design to every scientist!
Boltz’s Series A is led by @BessemerVP, following 50-fold growth in molecular token usage from our users since June and partnerships with 6 of the world’s 20 largest pharma companies.
Congratulations to the team!
We’ve raised $110M to bring AI-powered biomolecular design to every scientist!
Boltz’s Series A is led by @BessemerVP, following 50-fold growth in molecular token usage from our users since June and partnerships with 6 of the world’s 20 largest pharma companies.
Nima Shoghi retweeted
We’ve raised $110M to bring AI-powered biomolecular design to every scientist!
Boltz’s Series A is led by @BessemerVP, following 50-fold growth in molecular token usage from our users since June and partnerships with 6 of the world’s 20 largest pharma companies.
Nima Shoghi retweeted
EXCLUSIVE: Boltz says pharma usage of its AI drug design software is up 50x, raising a $110M Series A to double down and expand, @GabriCorso tells me
My latest for @endpts on another major AI bio raise in London: endpoints.news/ai-bio-startu…
Nima Shoghi retweeted
Honoured to speak at @MSKCancerCenter last week on using Boltz models to accelerate early-stage drug discovery for challenging targets. Having admired and benefited from MSK's research for years, it was humbling to be invited to speak there.
Thanks to MSK for organising!
Nima Shoghi retweeted
Reading group today. RFD4-Proteina: 158 of 188 designed binders bound TrkA below 1 µM. Next best method: 18 of 60. Nate Corley and @DidiKieran will present rfd4-proteina.org/
On Zoom 2pm ET / 8pm CET: hannes-stark.com/starkly-spe…
Nima Shoghi retweeted
Today at GTC, we’re excited to announce our collaboration with Bristol Myers Squibb to bring the latest Boltz models into BMS’s drug discovery workflows. @bmsnews @boltz_bio 🚀🧵
Nima Shoghi retweeted
Proud to be supporting this AI x bio hackathon in Berkeley next month!
Build at DNAForge’s AI × Biology Hackathon.
November 14th · Berkeley · $1,500+ in prizes
With @modal @boltz_bio @tamarindbio @talusbio @gxl_ai @benchflow_ai @SynphonyDev @GabriCorso @xdotli @Atelfo
Priority: October 25th
Apply in under 5 minutes:
dnaforge.com/hackathon
Nima Shoghi retweeted
Public preview of BioEmu2! @MSFTResearch AI for Science’s new foundation model for biomolecular structure, dynamics and function. Open weights, MIT license.
github.com/microsoft/bioemu2
Movie: BioEmu2-simulated binding of intrinsically disordered peptide PUMA to MCL-1 receptor. 🧵⬇️
Nima Shoghi retweeted
Correction: top-1 at MoML. Congrats @talthegal!
Tally Portnoi and I are releasing zPocket, a pocket prediction tool based on co-folding features (MoML top-4 papers), with performance similar to the IsoDDE and AnewDDE pocket predictors but fully reproducible and open (when using ESMFold2).
arxiv.org/abs/2610.17696
Nima Shoghi retweeted
Well that was something. Means a lot to have the backing of @JensenHuang and the @nvidia team.
Cheers to the UK’s AI builders. 🇬🇧
Tonight in London, @JensenHuang announced new investments in @boltz_bio, @ForesightWorks, @hivergeai, @PrimaMente, and Riverlane.
From new medicines to quantum computing, there’s plenty to build.
Cheers to the UK’s AI builders. 🇬🇧
Tonight in London, @JensenHuang announced new investments in @boltz_bio, @ForesightWorks, @hivergeai, @PrimaMente, and Riverlane.
From new medicines to quantum computing, there’s plenty to build.
🤖 Made with AI
Nima Shoghi retweeted
BoltzMol-1 can now design within WuXi GalaXi!
Adding new diversity to the virtual space searchable by BoltzMol-1, this 25B sized synthesis-ready compound library is now available in Boltz Lab and using our Boltz API.
Nima Shoghi retweeted
Boltz on Times Square! Proud to see our team be part of the Disruptors 60 Class of 2026 and to see our work bringing AI-based biomolecular design to every scientist recognized. Thank you to our team, our partners and the scientists building with Boltz!
Nima Shoghi retweeted
i was diagnosed with thyroid cancer many years ago purely by chance, because i had to get blood work for my US green card application (thank you, USCIS!). i was in my mid-30’s and was reasonably healthy (or so i believed.) this was shocking and totally unpredictable news to me. thanks to the amazing team of clinicians at NYU Langone, i successfully went through a total thyroidectomy followed by radioactive iodine therapy. but, it was truly the most uncertain and confusing period of my life.
this is when i first realized that no one can opt out of healthcare. being sick isn’t what you choose to or choose not to. it is something that unpredictably happens to all of us at some point for one reason or another. this is why it is a healthcare system that we collectively build and use to support each other at the society level. because it must support everyone, the complexity of creating, maintaining and improving this system is a Herculean effort that calls for all the help in the world.
today, i am announcing @OrtetAI together with my dear co-founders, @keunwoochoi, @HenriDwyer, @elmanmansimov, @causalclaudia and Jeff, to lend our support to improving the health of each and every one of us. Ortet’s goal is to create a technological foundation that will enable health systems to deliver predictably better care to each and every patient. this will only be possible by working closely with all stakeholders in the broader ecosystem, which is enabled in part by Ortet’s close partnership with Thoreau.
Ortet is taking the very first step of a long journey ahead, and at the end of this journey, i strongly believe we would be able to say that Ortet had contributed to building better, more predictable healthcare and thus to improving health of each and every one of us.
see ortet.ai/ for more!
Nima Shoghi retweeted
I’ve signed this letter alongside leaders from some of the UK’s best frontier technology startups, calling on the government to end restrictive employment practices that hold back our science and technology ecosystem. 🧵
Nima Shoghi retweeted
Since releasing BoltzMol-1 a couple of months ago, we've seen exciting successes with several partners. Today we're sharing another example from our scientific team: a new case study led by @GSmithOfficial on Werner helicase (WRN), a highly dynamic & difficult cancer target 🧪🧬






















